Accéder au contenu
Merck
  • Solid-phase molecularly imprinted pre-concentration and spectrophotometric determination of isoxicam in pharmaceuticals and human serum.

Solid-phase molecularly imprinted pre-concentration and spectrophotometric determination of isoxicam in pharmaceuticals and human serum.

Talanta (2009-02-11)
B Rezaei, S Mallakpour, N Majidi
RÉSUMÉ

A selective molecularly imprinted polymer (MIP) has been synthesized for isoxicam pre-concentration, followed by its spectrophotometric determination based on hydrogen bonding interactions between examined drug and alizarin yellow GG. This method is able to evaluate isoxicam in range of 1.0 x 10(-3) to 20.0 microg mL(-1), with a limit of determination of 1.0 ng mL(-1). The retention capacity and pre-concentration factor of prepared sorbent are 18.5 mg g(-1) and 200, respectively; and the prepared MIPs can be reused at least for five times. The MIP capability for isoxicam selection and extraction from the solution is higher than non-imprinted polymer (NIP). Under optimum conditions, this procedure can be successfully applied to assay trace amounts of isoxicam in pharmaceutical and biological samples.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Isoxicam, analytical standard